Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus oxaliplatin and S-1 as neoadjuvant therapy for resectable gastric cancer
ChiCTR2000035291Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Pathologic complete response rate. Started Jul 2020; status: recruiting.
02
Drugs
camrelizumaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000035291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035291.